Johnson College hosts Community Resource Fair
SCRANTON, LACKAWANNA COUNTY (WBRE/WYOU) — Over a dozen organizations and businesses are coming together at one college in Lackawanna County with a goal to strengthen the local community.
It's a rainy Tuesday morning at Johnson College in Scranton.
The campus looks to be empty, as the spring semester has come to an end, but inside, they're getting ready to welcome the public to its first-ever Community Resource Fair.
'It can tell people in this community that while they might think that they're facing a barrier to get into college, we have these organizations here to help them and help them overcome any obstacle they might have,' said Sam Lehman, community engagement coordinator at Johnson College.
Those obstacles might include transportation, housing, and childcare. That's why several groups, like Samantha Kovaleski with United Neighborhood Centers, are here to provide extra support.
'It's really great to be partnering with a college, especially you know something that is so hands-on, and it gets the students in and back into the workforce faster than you know going to a typical four-year college,' explained Kovalkeski.
Amazon announces $20B data center investment in Pa.
Angela Seibert, with Outreach Center for Community Resources, says her organization has a demand for people wanting to go back to school.
'We've definitely seen a huge uptick in the last five years we've grown immensely. In the last program year, I think we served about 110 people in our GED program, so that's a large number,' explained Seibert.
Nearly 50% of the two-year technical students at Johnson need more support to complete their college education.
Assisting not just students out of college, but also non-traditional students such as single parents or those working full-time, enrollment at Johnson College has gone up.
'With that, we've seen community needs and student needs increase as well, so we wanted to not only help our Johnson students, but also the students in general within our area,' said Tim Frank, associate director of community engagement at Johnson College.
Happening on Tuesday, the Community Resource Fair runs from 6:00 p.m. to 7:00 p.m. at its Scranton campus.
And if you're unable to attend tonight's Community Resource Fair, Johnson College has another one scheduled for August 12th.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison
Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax 1 Phase 2 CAPTIVATE long-term follow-up data further supports sustained efficacy and safety profile of fixed-duration ibrutinib plus venetoclax treatment in patients receiving frontline treatment for chronic lymphocytic leukaemia 2 Beerse, Belgium, June 12, 2025 (GLOBE NEWSWIRE) — Janssen-Cilag International NV, a Johnson & Johnson company, today announced new data from a matching-adjusted indirect comparison (MAIC) analysis assessing the efficacy of IMBRUVICA® (ibrutinib) in combination with venetoclax (I+V) vs acalabrutinib in combination with venetoclax (A+V) as fixed-duration (FD) treatments for adults with previously untreated chronic lymphocytic leukaemia (CLL).1 The data were featured in a poster presentation at the 30th European Hematology Association (EHA) Congress (Poster presentation #PF587) and reported that the I+V regimen yielded significantly better efficacy when compared to the A+V regimen.1 Patients treated with I+V were more likely to achieve disease clearance, as measured by undetectable minimal residual disease (uMRD) three months after the end of treatment (EOT+3), from both peripheral blood (PB) and bone marrow (BM).1 In addition to this, progression-free survival (PFS) significantly favoured I+V compared to A+V.1 'In the absence of head-to-head trials, clinicians need reliable tools to effectively compare treatment options and make the best possible choices for their patients,' said Talha Munir, M.D., Consultant in Clinical Haematology at St James's Hospital, Leeds, United Kingdom.* 'The matching-adjusted indirect comparison data presented at EHA suggests that ibrutinib plus venetoclax may offer meaningful clinical advantages over acalabrutinib plus venetoclax with patients more likely to achieve higher rates of undetectable minimal residual disease, three months after treatment. This may translate into more time in remission and longer progression-free survival – outcomes that matter deeply to both patients and the healthcare professionals who treat them.' Patients who met the AMPLIFY inclusion criteria from both the Phase 3 GLOW (NCT03462719) and Phase 2 CAPTIVATE (NCT02910583) studies were included in this analysis, and, after matching and balancing the treatment cohorts, comparative analyses between the trials suggested that I+V significantly reduced the risk of progression or death by 47 percent when compared to patients treated with A+V (hazard ratio [HR]: 0.53; 95 percent confidence interval [CI]: 0.33-0.85; p =0.0085).1,3,4,5 The results also suggested that patients treated with I+V were almost twice (95 percent CI: 1.47-2.41; p <0.0001) and 2.4 times (95 percent CI: 1.78-3.12; p <0.0001) more likely to achieve uMRD than A+V at EOT+3, in PB and BM, respectively.1 The GLOW and CAPTIVATE FD cohorts were based on individual patient-level data with a median follow-up of approximately 4.5 years, while the A+V cohort used aggregate level data from the AMPLIFY study with a median follow-up of approximately 3.4 years.1 Results from final analysis of CAPTIVATE Long-term follow-up results from the Phase 2 CAPTIVATE study data were presented as a poster at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (Poster presentation #219) and will also be presented as an encore oral presentation at EHA 2025 (Oral presentation #S156).6 The data reinforced the durable clinical benefit of frontline I+V.2 Phase 2 CAPTIVATE results demonstrated patients in the I+V FD cohort displayed a clinically meaningful PFS and overall survival (OS) vs the MRD-guided cohort.2 After a median follow-up of 68.9 months, the 5.5-year PFS and OS rates for all treated patients were 66 percent (95 percent CI: 58-72) and 97 percent (95 percent CI: 93-99), respectively.2 Additionally, the 5.5 year PFS rate in patients who achieved uMRD in the PB at the EOT was 71 percent (95 percent CI: 60-80).2 Furthermore, 1-year PFS and OS rates from the start of retreatment (with single-agent ibrutinib or FD I+V) were both 100 percent, whilst 2-year PFS and OS rates from the start of retreatment were 91 percent and 96 percent, respectively.2 No new safety signals were observed during the CAPTIVATE study since the previous follow-up, with COVID-19, diarrhoea and hypertension being the most frequently reported adverse events (AEs).2 In the total pooled CAPTIVATE population, 32 percent (n=64/202) of patients had progressive disease following 5.5 years of follow-up.2 Of the 53 patients with available samples, none had acquired resistance-associated mutations in BTK or PLCG2 .2 'The final analysis of CAPTIVATE highlights how ibrutinib continues to raise the bar in the treatment of chronic lymphocytic leukaemia, with durable minimal residual disease response, extended treatment-free intervals, and a tolerable safety profile,' said Ester in't Groen, EMEA Therapeutic Area Head Haematology, Johnson & Johnson Innovative Medicine. 'With the longest follow-up of any oral fixed-dose regimen, ibrutinib is setting a new standard for what patients and clinicians can expect from targeted therapies. We remain committed to advancing science in complex blood cancers and improving outcomes across the cancer care landscape.' 'The updates presented at EHA add to the growing body of evidence in support of ibrutinib, the most extensively studied Bruton's tyrosine kinase inhibitor, as the standard of care in the frontline treatment of chronic lymphocytic leukaemia,' said Jessica Vermeulen, Vice President, Lymphoma & Leukemia Disease Area Stronghold Leader, Johnson & Johnson Innovative Medicine. 'Offering patients not only more time, but also the option for treatment-free remissions continues to be our goal and we are proud of the incredible contribution ibrutinib has made since its first European approval in 2014.' About the MAIC analysis The objective of this analysis was to compare the progression-free survival (PFS) and undetectable minimal residual disease (uMRD) data from the fixed-duration (FD) ibrutinib + venetoclax (I+V) cohorts from the Phase 3 GLOW (NCT03462719) and Phase 2 CAPTIVATE (NCT02910583) studies against the Phase 3 AMPLIFY (NCT03836261) data.1 In absence of prospective head-to-head trials investigating different Bruton's tyrosine kinase inhibitors (BTKis) plus B-cell lymphoma 2 (Bcl-2) strategies, this study utilised matching-adjusted indirect comparison (MAIC) to obtain useful insights on comparative efficacy.1 Individual patient data from the FD I+V cohorts of the GLOW and CAPTIVATE studies were pooled and compared to aggregate published Intent-to-Treat (ITT) data of the acalabrutinib plus venetoclax (A+V) arm of the AMPLIFY study.1,3,4,5 A MAIC was performed following method published by Signorovitch et al. and guidelines from the National Institute for Health and Care Excellence (NICE).1,7 Patients who did not meet the inclusion criteria of AMPLIFY were excluded from the I+V pooled cohort to establish the I+V patient population for analysis.1 The remaining I+V patients were then reweighted so that the average baseline characteristics of the pooled I+V cohort matched those of the A+V patients in AMPLIFY.1 The reweighted outcomes from I+V were then compared to the reported outcomes for A+V using indirect treatment comparison.1 Relative effects were quantified using relative risk (RR) and hazard ratios (HR) with 95 percent confidence intervals.1 There are potential sources of bias that cannot be accounted for in MAIC, that should be considered when interpreting such data. Specifically, in this comparison, the measurement of progression was stricter in GLOW and CAPTIVATE, requiring computer or magnetic imaging regardless of suspected progression and the median follow-up was longer in I+V population.1 Both may have biased the PFS results in favour of A+V.1 Additionally, AMPLIFY reported multicolour flow cytometry use but with no details on the number of colours and comparability is assumed with the 8-colour assay used in I+V studies.1 As in any non-randomised comparison there may be additional unreported clinically important prognostic patient baseline characteristics which cannot be accounted for.1 For example, Cumulative Illness Rating Scale score data was not collected in CAPTIVATE and therefore could not be used in matching.1 About CAPTIVATE The Phase 2 CAPTIVATE study ( NCT02910583 ) evaluated previously untreated adult patients with chronic lymphocytic leukaemia (CLL), who were 70 years or younger, including patients with high-risk disease, in two cohorts with combined median age of 60 years: a minimal residual disease (MRD)-guided cohort (n=43) and an FD cohort (n=159; median age).2,4,8 Patients in the FD cohort received three cycles of ibrutinib lead-in followed by 12 cycles of I+V (oral ibrutinib [420 mg/d]; oral venetoclax [five-week ramp-up to 400 mg/d]) and the primary endpoint was complete response rate.4 In the MRD cohort, after completion of three cycles ibrutinib lead-in followed by 12 cycles I+V, patients with confirmed uMRD were randomly assigned to double-blind treatment with placebo, or continuous ibrutinib.4 The primary endpoint was one-year disease-free survival.4 About the GLOW study The GLOW study ( NCT03462719 ) is a randomised, open-label, Phase 3 trial that evaluated the efficacy and safety of frontline, FD I+V versus chlorambucil plus obinutuzumab in adult patients with CLL who are (a) ≥65 years old, or (b) 18-64 years old with a Cumulative Illness Rating Scale score of greater than six or creatinine clearance less than 70 mL/min, who had active disease requiring treatment per the International Workshop on CLL criteria.3 About ibrutinib Ibrutinib is a once-daily oral medication that is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company.9 Ibrutinib blocks the Bruton's tyrosine kinase (BTK) protein, which is needed by normal and abnormal B-cells, including specific cancer cells, to multiply and spread.10 By blocking BTK, ibrutinib may help move abnormal B-cells out of their nourishing environments and inhibits their proliferation.11 Ibrutinib is approved in more than 100 countries and has been used to treat more than 325,000 patients worldwide.12 There are more than 50 company-sponsored clinical trials, including 18 Phase 3 studies, over 11 years evaluating the efficacy and safety of ibrutinib.10,13 In October 2021, ibrutinib was added to the World Health Organization's Model Lists of Essential Medicines (EML), which refers to medicines that address global health priorities and which should be available and affordable for all.14 Ibrutinib was first approved by the European Commission (EC) in 2014, and approved indications to date include:10 As a single agent or in combination with rituximab or obinutuzumab or venetoclax for the treatment of adult patients with previously untreated CLL As a single agent or in combination with bendamustine and rituximab (BR) for the treatment of adult patients with CLL who have received at least one prior therapy As a single agent for the treatment of adult patients with relapsed or refractory (RR) mantle cell lymphoma (MCL) As a single agent for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. In combination with rituximab for the treatment of adult patients with WM For a full list of adverse events and information on dosage and administration, contraindications and other precautions when using ibrutinib please refer to the Summary of Product Characteristics . About Chronic Lymphocytic Leukaemia CLL is typically a slow-growing blood cancer of the white blood cells.15 The overall incidence of CLL in Europe is approximately 4.92 cases per 100,000 persons per year and it is about 1.5 times more common in men than in women (based on individuals diagnosed 2000-2002).16 CLL is predominantly a disease of the elderly, with a median age of 72 years at diagnosis.17 While patient outcomes have dramatically improved in the last few decades, the disease is still characterised by consecutive episodes of disease progression and the need for therapy.18 Patients are often prescribed multiple lines of therapy as they relapse or become resistant to treatments.19 About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at . Follow us at . Janssen-Cilag International NV, Janssen Pharmaceutica NV, Janssen-Cilag Limited, Janssen Biotech, Inc., and Janssen Research & Development, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of daratumumab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. *Talha Munir, M.D., Consultant in Clinical Haematology at St James's Hospital, Leeds, United Kingdom, has provided consulting, advisory, and speaking services to Janssen-Cilag International NV; he has not been paid for any media work. 1 Munir T, et al., Cross-Study Comparison of Ibrutinib in Combination with Venetoclax (I+V) vs Acalabrutinib in Combination with Venetoclax (A+V) in Subjects with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Poster presentation at 2025 European Hematology Association (EHA) Congress; June 12–15, 2025. [Poster PF587]. 2 Ghia P, et al. Final Analysis of Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study. Oral presentation at 2025 European Hematology Association (EHA) Congress; June 12–15, 2025. [Oral S156]. 3 A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW). Available at: Last accessed: June 2025. 4 Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) (CAPTIVATE). Available at: Last accessed: June 2025. 5 Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY). Available at: Last accessed: June 2025. 6 Ghia P, et al. Final Analysis of Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Phase 2 CAPTIVATE Study. Poster presentation at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting; May 30–June 3, 2025. [Poster #219]. 7 Signorovitch JE, et al. Matching-adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research. Value Health, 2012; 15: 940-947. 8 Jacobs R, et al., Outcomes in High-risk Subgroups After Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Up To 5.5 years of Follow-up in the Phase 2 CAPTIVATE Study. Poster presentation at 2024 European Hematology Association (EHA) Hybrid Congress; June 13–16, 2024. [Poster P675]. 9 European Medicines Agency. IMBRUVICA Summary of Product Characteristics. April 2025. Available at: Last accessed: June 2025. 10 Turetsky A, et al. Single cell Imaging of Bruton's tyrosine kinase using an Irreversible Inhibitor. Sci Rep. 2014; 4: 4782. 11 de Rooij MF, et al. The Clinically Active BTK Inhibitor PCI-32765 targets B-cell Receptor- and Chemokine-controlled Adhesion and Migration in Chronic Lymphocytic Leukemia. Blood. 2012; 119(11): 2590-2594. 12 J&J Data on File (RF-465355). Patients Treated on Imbruvica Worldwide. May 2025. 13 Pollyea DA, et al. A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. Blood. 2009; 114(22): 3713. 14 World Health Organization. WHO Prioritizes Access to Diabetes and Cancer Treatments in New Essential Medicines Lists. Available at: Last accessed: June 2025. 15 American Cancer Society. What is Chronic Lymphocytic Leukemia? Available at: Last accessed: June 2025. 16 Sant M, et al. Incidence of Hematologic Malignancies in Europe by Morphologic Subtype: Results of the HAEMACARE project. Blood. 2010; 116:3724–34. 17 Eichhorst B, et al. Chronic Lymphocytic Leukaemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up Ann Oncol. 2021; 32(1): 23-33. 18 Moreno C. Standard Treatment Approaches for Relapsed/refractory Chronic Lymphocytic Leukemia after Frontline Chemoimmunotherapy. Hematology Am Soc Hematol Educ Program. 2020; 2020: 33-40. 19 Bewarder M, et al. Current Treatment Options in CLL. Cancers (Basel). 2021;13(10): 2468. CP-523458 June 2025 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
6 hours ago
- Yahoo
Central Ohio mover claims Texas company stiffed him for work
COLUMBUS, Ohio (WCMH) — Some central Ohioans are raising the alarm about a Texas-based moving company, saying they didn't get paid for their work. Caddy Moving is based in Austin, Texas, but hires people all over the United States for moving jobs, including in Columbus. One man reached out to NBC4 Investigates after, he claims, the company did not pay him; NBC4 found dozens of complaints like his from central Ohio and beyond. The man who called NBC4 Investigates found a help-wanted ad on Craigslist looking to hire movers. He needed money for his kids. Multiple teenagers allegedly open fire at police officers near south Columbus park A long day of moving is hard enough, but what happened to this man, having to ask for his pay day after day, might be even harder. 'I don't think you should treat people that way,' Bruce Johnson, who did a job with Caddy Moving, said. Johnson got in touch with Caddy Moving. Texts show an understanding he was to be paid the day of the moving job, May 25, or at least within 24 hours. 'From my understanding that once the job was complete and they speak to the homeowners and then we'll be paid right after,' Johnson said. Final full moon of Spring, the 'Strawberry Moon,' glows over central Ohio Texts Johnson shared show he worked the job, moving someone into a home in Hilliard, but he did not get paid that day, like he was told. 'They keep saying we're going to pay you, and then I get a text at 1 in the morning saying, 'Hey, we sent you a pay,' then they didn't send the pay,' Johnson said. Then he got a text saying there was an issue with the payment system. 'Then I find their reviews,' Johnson said. NBC4 Investigates looked into Caddy Moving and found dozens of complaints just like Johnson's, across Google, the Better Business Bureau and Trust Pilot, a website that hosts reviews of businesses worldwide. Some read: 'Company is refusing to pay for labor,' 'This company does not pay what they're advertising on their website. After the work is complete and their customer is satisfied, they'll stop responding' and 'Promised that they'd pay me if I removed my Google review, and because I refused to remove it, they're still refusing to pay me.' Chemical leak at explosives manufacturing plant prompted evacuations in Vinton County 'I just felt bamboozled and just worried I wasn't going to get paid,' Johnson said. Caddy Moving responded to NBC4 Investigates on June 11. 'We had some issues with Venmo and PayPal recently,' Caddy Moving CEO Zach Richards said. 'We did have a couple of our systems actually get locked up on us and we worked through those with our guys. We actually launched a hotline for guys to reach out to.' Caddy Moving said that as a startup, it does not have everything figured out yet, but takes accountability for the payment issues. We asked about the reviews across the websites as well. 'As far as the Trustpilot, Yelp, we were not signed up on any of those platforms we don't monitor them so as you could imagine, those that have negative feedback to share they are going to go to those platforms, but we did not sign up on those platform,' Richards said. 'We don't have everything figured out. Of course. But no, we fully take accountability for having delays on payments.' Richards said those with complaints can reach out to him at zach@ or by calling the help line at 888-788-8542. More than 400,000 Ohioans see driver's license suspensions lifted under new law Caddy Moving is based out of Texas and NBC4 Investigates found the attorney general there has also received complaints. Johnson reached out to them and to NBC4 Investigates and finally, two and a half weeks after the job, he was paid the money he was owed, but said he knows others are still waiting. 'I just want to be done with them,' Johnson said. 'I hope they get it together and stop treating people like that.' Other reviews and those we have heard from are customers saying the company canceled last minute or movers stretched the time of the move and they had to pay more. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
10 hours ago
- Yahoo
Aldermen advance measure allowing Airbnb bans in Chicago precincts
Aldermen took a step Wednesday toward giving themselves the power to ban Airbnb's and other short-term rentals from opening in their wards. The City Council's License and Consumer Protection Committee advanced the ordinance that would allow aldermen to unilaterally block new short-term rentals one precinct at a time. It could now face a final vote by all aldermen as soon as next week. Sponsor Ald. Anthony Napolitano, 41st, called the city's current ordinance made a decade ago 'extremely sloppy.' The existing law allows short-term rentals to be blocked only when 25% of a precinct's registered voters sign a petition calling for it. 'This is the only ordinance written in the city of Chicago where, when there is a problem in the industry, the onus is put on residents to fix it,' Napolitano said. The Far Northwest Side alderman's ordinance seeks to reverse that, allowing aldermen to block short-term rentals in a precinct on their own. It would then give companies the chance to overturn the ban by collecting signatures from 10% of the precinct's voters. Most aldermen in attendance backed the ordinance in a voice vote. Several cited issues in their ward with disruptive parties at short-term rentals, a problem Ald. Brendan Reilly, 42nd, said is 'on steroids' in dense downtown high rises. 'The guests are taking over common areas, pool decks, lobbies, fitness rooms,' he said. 'With the late night parties and noise complaints, et cetera, God help you if you own a condo next to one of these nightly rental units.' Napolitano argued the ordinance will not hurt short-term rental companies, but instead simply gives aldermen a tool to advocate for residents when issues arise. But Airbnb is strongly opposed to the proposal. 'Alderman Napolitano's ordinance amendment is an over-broad and misguided violation of Chicagoans' property rights, which would punish responsible homeowners and local businesses who rely on the income from travel on short-term rentals — especially in neighborhoods outside of Chicago's traditional tourism hubs,' Airbnb spokesperson Jonathan Buckner said in a statement Wednesday. Mayor Brandon Johnson is continuing to not take a side on the issue. Asked where he stood on the ordinance at a Wednesday morning news conference, he said he wanted to 'continue to ensure that we are building a safe, affordable city.' 'This particular measure, quite frankly, I'll have to look into a little bit deeper,' Johnson said. 'But I know that there are a number of alders who mean well and are trying to show up for their particular pocket of the city.' Several aldermen noted the absence of staff from Johnson's Department of Business Affairs and Consumer Protection, adding that they wished someone could answer questions about how bans could affect tax revenue. Alds. Matt O'Shea, 19th, and Bill Conway, 34th, voted against the measure, with O'Shea noting taxes on the rentals sent around $4 million to fight domestic violence. 'Have we thought of how we are going to replace that?' O'Shea asked. 'It's been my experience working with Airbnb that when a problem is identified, it's addressed.' Ald. Marty Quinn, 13th, used the city's current process requiring residents' signatures to ban short-term rentals from every precinct in his Southwest Side ward. The whole-ward ban took 12,000 signatures and seven years to complete, he said. The ward is '95% single family dwellings,' and short-term rentals 'would have an adverse impact on our quality of life,' Quinn said. Asked what he thinks of Airbnb's argument that the ban is similar to historic racist efforts to keep Black and Latino people out of certain neighborhoods, Quinn called it a 'desperate statement from a company who got exactly what they wanted' when the original ordinance passed. 'I'm not saying that Airbnb isn't good in some parts of the city,' he said. 'It's just not good in the Bungalow Belt, and I have 12,000 signatures that would suggest that.' Aldermen also Wednesday advanced a measure to crack down on illegal pedicabs with potential impoundments.
